In this study, we observed lower metabolic ratios in patients with NAFLD compared to those with HCV infection which raises the possibility that the influence of liver disease may mask the influence of UGT1A1*28 polymorphism on the pharmacokinetics of silymarin. Here, UGT1A1 is linked to metabolic dysfunction-associated steatotic liver disease.